Modified FOLFOXIRI plus cetuximab (cet) as induction treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Preliminary results of the phase II randomized Macbeth trial by GONO group.

被引：3
|
作者：
Cremolini, Chiara
Loupakis, Fotios
Salvatore, Lisa
Lonardi, Sara
Battaglin, Francesca
Gamucci, Teresa
Grande, Roberta
Di Fabio, Francesca
Liimpe, Fabiola Lorena Rojas
Ferrari, Laura
Casagrande, Mariaelena
Lucchesi, Sara
Tonini, Giuseppe
Banzi, Maria
Valsuani, Chiara
Corsi, Domenico C.
Fontanini, Gabriella
Tomcikova, Daniela
Boni, Luca
Falcone, Alfredo
机构：
[1] Azienda Osped Univ Pisana, Ist Toscano Tumori, UO Oncol Med 2, Pisa, Italy
[2] Azienda Osped Univ Pisana, UO Oncol Med 2, Pisa, Italy
[3] Ist Oncol Veneto IOV IRCCS, Med Oncol 1, Padua, Italy
[4] IRCSS, Ist Oncol Veneto, Med Oncol 1, Padua, Italy
[5] ASL Frosinone, Med Oncol Unit, Sora, Italy
[6] ASL Frosinone, Med Oncol Unit, Frosinone, Italy
[7] St Orsola Marcello Malpighi Hosp, Med Oncol Unit, Bologna, Italy
[8] Azienda Osped Univ, Udine, Italy
[9] USL 5 Pontedera, Div Med Oncol, Pontedera, Italy
[10] Campus Biomed Univ Rome, Dept Med Oncol, Rome, Italy
[11] Arcispedale Santa Maria Nuova, Reggio, Italy
[12] Osped Versilia, UO Oncol Med, Viareggio, Italy
[13] Osped San Giovanni Calibita, Fatebenefratelli Isola Tiberina, Rome, Italy
[14] Univ Pisa, Div Anat Patol, Dipartimento Patol Chirurg Med & Mol & Area Crit, Pisa, Italy
[15] Ist Toscano Tumori, Florence, Italy
[16] AOU Careggi, Clin Trial Coordinating Ctr, Ist Toscano Tumori ITT, Florence, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.3596
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3596
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): results of the phase II randomized MACBETH trial by GONO
    Antoniotti, C.
    Cremolini, C.
    Loupakis, F.
    Bergamo, F.
    Grande, R.
    Tonini, G.
    Silvio, K. Garattini
    Masi, G.
    Battaglin, F.
    Lucchesi, S.
    Salvatore, L.
    Corsi, D.
    Di Fabio, F.
    Banzi, M.
    Moretto, R.
    Sensi, E.
    Rossini, D.
    Tomcikova, D.
    Fontanini, G.
    Zagonel, V.
    Boni, L.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 : 121 - 122
  • [2] Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): the phase II randomized MACBETH trial by GONO
    Antoniotti, C.
    Cremolini, C.
    Loupakis, F.
    Bergamo, F.
    Garattini, S. K.
    Grande, R.
    Tonini, G.
    Masi, G.
    Schirripa, M.
    Bonotto, M.
    Ruman, L.
    Lucchesi, S.
    Rossini, D.
    Corsi, D.
    Ronzoni, M.
    Llimpe, F. L. Rojas
    Fontanini, G.
    Boni, L.
    Zagonel, V.
    Delliponti, L.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [3] Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): The phase II randomized MACBETH trial by GONO
    Cremolini, C.
    Antoniotti, C.
    Loupakis, F.
    Bergamo, F.
    Ferrari, L.
    Grande, R.
    Tonini, G.
    Masi, G.
    Schirripa, M.
    Bonotto, M.
    Solda, C.
    Lucchesi, S.
    Rossini, D.
    Corsi, D.
    Ronzoni, M.
    Llimpe, F. L. Rojas
    Fontanini, G.
    Boni, L.
    Zagonel, V.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [4] Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): Results of the phase II randomized MACBETH trial by GONO.
    Antoniotti, Carlotta
    Cremolini, Chiara
    Loupakis, Fotios
    Bergamo, Francesca
    Grande, Roberta
    Tonini, Giuseppe
    Garattini, Silvio Ken
    Masi, Gianluca
    Battaglin, Francesca
    Lucchesi, Sara
    Salvatore, Lisa
    Corsi, Domenico C.
    Di Fabio, Francesca
    Banzi, Maria
    Sensi, Elisa
    Tomcikova, Daniela
    Fontanini, Gabriell
    Zagonel, Vittorina
    Boni, Luca
    Falcone, Alfredo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group.
    Falcone, Alfredo
    Cremolini, Chiara
    Masi, Gianluca
    Lonardi, Sara
    Zagonel, Vittorina
    Salvatore, Lisa
    Trenta, Patrizia
    Tomasello, Gianluca
    Ronzoni, Monica
    Ciuffreda, Libero
    Zaniboni, Alberto
    Tonini, Giuseppe
    Buonadonna, Angela
    Valsuani, Chiara
    Chiara, Silvana
    Carlomagno, Chiara
    Boni, Corrado
    Marcucci, Lorenzo
    Boni, Luca
    Loupakis, Fotios
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: Results of the phase II AVETRIC trial by GONO
    Conca, V.
    Antoniotti, C.
    Bergamo, F.
    Pietrantonio, F.
    Rossini, D.
    Scartozzi, M.
    Perissinotto, E.
    Leone, A.
    Pusceddu, V.
    Borelli, B.
    Cavanna, L.
    Latiano, T.
    Santini, D.
    Masi, G.
    Salvatore, L.
    Frassineti, G.
    Leone, F.
    Tamberi, S.
    Boni, L.
    Cremolini, C.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S173 - S173
  • [7] Modified FOLFOXIRI plus cetuximab and avelumab as initial therapy in RAS wild-type unresectable metastatic colorectal cancer: Results of the phase II AVETRIC trial by GONO
    Conca, Veronica
    Antoniotti, Carlotta
    Bergamo, Francesca
    Pietrantonio, Filippo
    Rossini, Daniele
    Scartozzi, Mario
    Perissinotto, Eleonora
    Leone, Alberto Giovanni
    Valeria, Pusceddu
    Borelli, Beatrice
    Cavanna, Luigi
    Latiano, Tiziana Pia
    Santini, Daniele
    Masi, Gianluca
    Salvatore, Lisa
    Frassineti, Luca
    Leone, Francesco
    Tamberi, Stefano
    Boni, Luca
    Cremolini, Chiara
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: Results of the phase II randomized AtezoTRIBE study by GONO
    Cremolini, C.
    Rossini, D.
    Antoniotti, C.
    Pietrantonio, F.
    Lonardi, S.
    Salvatore, L.
    Marmorino, F.
    Borelli, B.
    Ambrosini, M.
    Barsotti, G.
    Di Stefano, B.
    Masi, G.
    Boccaccino, A.
    Tamberi, S.
    Tamburini, E.
    Frassineti, L. G.
    Simionato, F.
    Fontanini, G.
    Boni, L.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1294 - S1295
  • [9] FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (mCRC): Updated survival results of the phase III TRIBE trial by the GONO group.
    Cremolini, Chiara
    Loupakis, Fotios
    Masi, Gianluca
    Zagonel, Vittorina
    Bergamo, Francesca
    Salvatore, Lisa
    Cortesi, Enrico
    Tomasello, Gianluca
    Ronzoni, Monica
    Pinta, Francesco
    Zaniboni, Alberto
    Tonini, Giuseppe
    Buonadonna, Angela
    Amoroso, Domenico
    Sonaglio, Claudia
    De Stefano, Alfonso
    Boni, Corrado
    Allegrini, Giacomo
    Boni, Luca
    Falcone, Alfredo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [10] FOLFOXIRI VERSUS FOLFIRI AS FIRST-LINE TREATMENT IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS: PRELIMINARY SAFETY RESULTS OF A RANDOMIZED PHASE III TRIAL OF THE GRUPPO ONCOLOGICO NORD OVEST (GONO)
    Falcone, A.
    Masi, G.
    Allegrini, G.
    Brunetti, I.
    Pfanner, E.
    Bertetto, O.
    Evangelista, W.
    Crino, L.
    Benedetti, G.
    Cortesi, E.
    Picone, V.
    Rosso, R.
    Chiara, S.
    Vitello, S.
    Merlano, M.
    Granetto, C.
    Fioretto, L.
    Ribecco, A.
    Alabiso, O.
    Ostellino, O.
    Porcile, G.
    Pucci, F.
    Bagnulo, A.
    Di Lieto, M.
    Filidei, M.
    Cupini, S.
    Marcucci, L.
    Barbara, C.
    Andreuccetti, M.
    Ricci, S.
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 58 - 58
12345